Erica F. Andersen

Erica F. Andersen, PhD, FACMG

Languages spoken: English, Spanish

Academic Information

Departments Primary - Pathology

Board Certification

  • American Board of Medical Genetics (Clinical Cytogenetics)
  • American Board of Medical Genetics and Genomics (Laboratory Genetics and Genomics)

Research Interests

  • Cytogenetics
  • Genomics
  • Constitutional and Acquired Genetic Abnormalities
  • Heritable Genetic Conditions
  • Hematologic Neoplasms

Erica Andersen is an Associate Professor of Clinical Pathology at the University of Utah and is the Head of Clinical Operations for Cytogenetics and Molecular Genetics at ARUP Laboratories. She received a PhD in Genetics from the University of Wisconsin-Madison and completed a Clinical Cytogenetics fellowship at ARUP Laboratories and the University of Utah. Dr. Andersen is board certified in Clinical Cytogenetics and Laboratory Genetics and Genomics by the American Board of Medical Genetics and Genomics and is a fellow of the American College of Medical Genetics and Genomics. Her professional interests include improving diagnostics, interpretative tools, and laboratory standards for cytogenetic and genomic testing.

Education History

Fellowship University of Utah and ARUP Laboratories
 Fellow
Doctoral Training University of Wisconsin-Madison
 PhD
Undergraduate Macalester College
 BA

Selected Publications

Journal Article

  1. Gonzales PR, Andersen EF, Brown TR, Horner VL, Horwitz J, Rehder CW, Rudy NL, Robin NH, Thorland EC, on behalf of the ACMG Laboratory Quality Assurance Committee (2021). Interpretation and reporting of large regions of homozygosity and suspected consanguinity/uniparental disomy, 2021 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 24(2), 255-261. (Read full article)
  2. Thaxton C, Good ME, DiStefano MT, Luo X, Andersen EF, Thorland E, Berg J, Martin CL, Rehm HL, Riggs ER, ClinGen Gene Curation Working Group, ClinGen Dosage Sensitivity Working Group (2021). Utilizing ClinGen gene-disease validity and dosage sensitivity curations to inform variant classification. Hum Mutat, 43, 1031-1040. (Read full article)
  3. Zhou XA, Yang J, Ringbloom KG, Martinez-Escala ME, Stevenson KE, Wenzel AT, Fantini D, Martin HK, Moy AP, Morgan EA, Harkins S, Paxton CN, Hong B, Andersen EF, Guitart J, Weinstock DM, Cerroni L, Choi J, Louissaint A (2020). Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. Blood Adv, 5(3), 649-661. (Read full article)
  4. Ballout RA, Dickerson C, Wick MJ, Al-Sweel N, Openshaw AS, Srivastava S, Swanson L, Bramswig NC, Kuechler A, Hong B, Fleming LR, Curry KT, Robertson SP, Andersen EF, El-Hattab AW (2020). Int22h1/Int22h2-mediated Xq28 duplication syndrome: de novo duplications, prenatal diagnoses, and additional phenotypic features. Hum Mutat, 41(7), 1238-1249. (Read full article)
  5. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, South ST, Thorland EC, Pineda-Alvarez D, Aradhya S, Martin CL (2019). Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genetics in Medicine, 22(2), 245-257. (Read full article)
  6. Paulraj P, Diamond S, Razzaqi F, Ozeran JD, Longhurst M, Andersen EF, Toydemir RM, Hong B (2019). Pediatric acute myeloid leukemia with t(7;21)(p22;q22). Genes Chromosomes Cancer, 58(8), 551-557. (Read full article)
  7. Herriges JC, Brown S, Longhurst M, Ozmore J, Moeschler JB, Janze A, Meck J, South ST, Andersen EF (2018). Identification of two 14q32 deletions involving DICER1 associated with the development of DICER1-related tumors. Eur J Med Genet, 62(1), 9-14. (Read full article)
  8. Paulraj P, Bosworth M, Longhurst M, Hornbuckle C, Gotway G, Lamb AN, Andersen EF (2019). A Novel Homozygous Deletion within the FRY Gene Associated with Nonsyndromic Developmental Delay. Cytogenet Genome Res, 159(1), 19-25. (Read full article)
  9. Riggs ER, Nelson T, Merz A, Ackley T, Bunke B, Collins CD, Collinson MN, Fan YS, Goodenberger ML, Golden DM, Haglund-Hazy L, Krgovic D, Lamb AN, Lewis Z, Li G, Liu Y, Meck J, Neufeld-Kaiser W, Runke CK, Sanmann JN, Stavropoulos DJ, Strong E, Su M, Tayeh MK, Kokalj Vokac N, Thorland EC, Andersen E, Martin CL (2018). Copy number variant discrepancy resolution using the ClinGen dosage sensitivity map results in updated clinical interpretations in ClinVar. Hum Mutat, 39(11), 1650-1659. (Read full article)
  10. Zhou XA, Louissaint A Jr, Wenzel A, Yang J, Martinez-Escala ME, Moy AP, Morgan EA, Paxton CN, Hong B, Andersen EF, Guitart J, Behdad A, Cerroni L, Weinstock DM, Choi J (2018). Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. J Invest Dermatol, 138(11), 2365-2376. (Read full article)
  11. Andersen EF, Paxton CN, OMalley DP, Louissaint A Jr, Hornick JL, Griffin GK, Fedoriw Y, Kim YS, Weiss LM, Perkins SL, South ST (2017). Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology. Mod Pathol, 30(9), 1321-1334. (Read full article)
  12. Paxton CN, OMalley DP, Bellizzi AM, Alkapalan D, Fedoriw Y, Hornick JL, Perkins SL, South ST, Andersen EF (2017). Genetic evaluation of juvenile xanthogranuloma: genomic abnormalities are uncommon in solitary lesions, advanced cases may show more complexity. Mod Pathol, 30(9), 1234-1240. (Read full article)
  13. Andersen EF, Baldwin EE, Ellingwood S, Smith R, Lamb AN (2014). Xq28 duplication overlapping the int22h-1/int22h-2 region and including RAB39B and CLIC2 in a family with intellectual and developmental disability. Am J Med Genet A, 164A(7), 1795-801. (Read full article)

Review

  1. Lu X, Andersen EF, Banerjee R, Eno CC, Gonzales PR, Kumar S, Lager AM, Miron PM, Pugh T, Quintero-Rivera F, Thurston VC, Wolff DJ, Zhao J, Fonseca R, Baughn LB (2025). Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group. [Review]. Blood Cancer J, 15(1), 86. (Read full article)

Abstract

  1. Longhurst M, Aston E, Zockle J, Zhou W, Rowe L, Frizzell K, Fredrickson E, OBrien K, Priest M, Clark C, Hong BAndersen E (March 2023). Validation of a Digital FISH Analysis Workflow in an Academic Reference Laboratory [Abstract]. 1(1, SUPP), 100469.
  2. LaGrave D, Lasher R, Bosworth M, Openshaw A, Rudd K, Andersen E (March 2023). Prenatal Cytogenetic Test Review Adds Value to Clinical Care – Illustrated by Example Cases [Abstract]. 1(1, SUPP), 100654.
  3. Herriges J, Runke CK, Lewis ZK, Pizzo L, Coe B, Conlin LK, Hilton BA, Levy B, Vaags AK, Zhang S, Martin CLAndersen EF (March 2023). Evaluating novel dosage sensitivity predictors for inclusion in the classification of recurrent copy number variants [Abstract]. 1(1, SUPP), 100532.
  4. Lewis Z, Reich D, Clyde B, ZoBell S, Quigley DAndersen E (March 2023). Reinterpretation of Clinical Copy Number Variants: A Practical Approach for Implementation as a Routine Laboratory Practice [Abstract]. 1(1, SUPP), 100547.
  5. Anderson H, Andersen E, Rudd K, Wen T, Bosworth M (March 2023). Impact of NIPS Outside of Scope Reporting on Fetal and Maternal Cytogenetic Testing [Abstract]. 1(1, SUPP), 100658.
  6. Zhao J, Lewis Z, Reich D, Chapin A, Clayton A, Clyde B, Cox J, Fulmer M, Hong B, Lamb A, Mani C, Pizzo L, Quigley D, Rushton P, Schultz R, Tidwell T, Wen T, Zepeda-Mendoza C, Andersen E (March 2022). Implementation of 2019 ACMG technical standards for the interpretation and reporting of constitutional CNVs: Experiences from an academic reference laboratory. [Abstract]. 24(3), S367.
  7. Quigley D, Lewis ZK, Tidwell T, Clayton A, Chandler B, Cox JL, Hong B, Lamb AN, Mowery-Rushton P, Schultz R, Toydemir R, Xu X, Andersen E (April 2021). Reevaluation of copy number variant (CNV) classifications in the clinical laboratory setting: challenges, insights, and experiences with a laboratory-initiated process.  [Abstract]. 252(S1), S15.
  8. Chandler B, Zhou W, Longhurst M, Rowe L, Siady D, Priest M, Clark C, Andersen EF, Quigley DI, Lamb AN (April 2021). Validation and implementation of BioDot instruments for semi-automated FISH slide processing [Abstract]. 252(S1), S4.
  9. Riggs E, Good M, Andersen E, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, Thorland EC, Pineda-Alvarez D, Aradhya S, Martin CL (April 2021). A web-based educational program to support the updated ACMG/ ClinGen technical standards for constitutional copy number variant classification [Abstract]. 132(S1), S235.
  10. Andersen E, Herriges J, Coe B, Conlin L, Goodenberger M, Hilton B, Jobanputra V, Levy B, Paulraj P, Riggs ER, Runke C, Schleede J, Speevak M, Zhang S, Thorland, Martin CL (April 2021). Standardizing recurrent copy number variant classification-from benign to reduced and high penetrance regions [Abstract]. 252(S1), S1-S2.
  11. Good M, Andersen E, Clayton A, Zhao J, Martin C, Riggs E, ClinGen Dosage Sensitivity Working Group (April 2021). Utilizing population-based genomic data to expedite the curation of genes and genomic regions for the ClinGen "dosage sensitivity unlikely" classification [Abstract]. 132(S1), S228-S229.
  12. Andersen EF, Zockle J, Chandler B, Delgado K, Quigley D, Toydemir R (2018). Development of an evidence-based algorithm to guide IGH-based reflex testing for plasma cell neoplasms [Abstract]. Blood, 132(132), 5586.
  13. Andersen E, Burnside R, Coe B, Conlin L, Herriges J, Higginbotham T, Hilton B, Jobanputra V, Kearney H, Ouyang K, Paulraj P, Riggs E, Rowsey R, Speevak M, Thorland E, Zhang L, Martin C, on behalf of the Clinical Genome Resource ClinGen (June 2018). Dosage Sensitivity Curation of Recurrent Copy Number Variant Regions. 2018 American Cytogenomics Conference [Abstract]. Cancer Genetics, 224-225(August 2018), 61.
  14. Zockle J, Chandler B, Delgado K, Quigley D, Toydemir R, Andersen E (June 2018). An evidence-based approach to guide IGH-based reflex testing for plasma cell neoplasms. 2018 American Cytogenomics Conference [Abstract]. Cancer Genetics, 224-225(August 2018), 53.
  15. Longhurst MC, Salama M, VanNess M, Kovacsovics TJ, Rodgers GM, Shami PJ, Deininger MW, South ST, Andersen EF (November 2016). Increased sensitivity for detection of genomic abnormalities from plasma cell-free DNA in myelodysplastic syndromes by SNP-Array [Abstract]. The Journal of Molecular Diagnostics, 18(6), 1052.
  16. Andersen EF, Salama ME, Sederberg MC, Toydemir RM, Kovacsovics TJ, Parker CJ, Rodgers GM, Shami PJ, Deininger MW, South ST (April 2015). Evaluating the clinical utility of peripheral blood samples for molecular evaluation of MDS by SNP-A [Abstract]. Leukemia Research, 39(Supp 1), S72.